Concepedia
Statistics
Publications
4
Citations
236
H-Index
Active since
2020
Affiliations
D. E. Shaw Research(Current)
Columbia University
Relay Therapeutics (United States)
Kamil Bruderek is an author at D. E. Shaw Research specializing in pharmacology, drug design, and targeted cancer therapy.
Publications per year
2020–2024
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
Vivek Subbiah, Vaibhav Sahai, Dejan Maglic et al. · Cancer Discovery · 2023 · 119 citations · Full text
Medicine, Oncology, Pharmacology +16
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2
Heike Schönherr, Pelin Ayaz, Alexander M. Taylor et al. · Proceedings of the National Academy of Sciences · 2024 · 66 citations · Full text
Pharmacy, Medicinal Chemistry, Pharmacology +14
Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time
Avinash Khanna, Alexandre Côté, Shilpi Arora et al. · ACS Medicinal Chemistry Letters · 2020 · 33 citations · Full text
Medicine, Medicinal Chemistry, Pharmacology +15
Abstract 1455: RLY-4008, a novel precision therapy for FGFR2-driven cancers designed to potently and selectively inhibit FGFR2 and FGFR2 resistance mutations
Jessica B. Casaletto, Dejan Maglic, B. Barry Touré et al. · Cancer Research · 2021 · 18 citations
Pharmacy, Oncology, Pharmacology +14
1–4 of 4